<DOC>
	<DOC>NCT02931565</DOC>
	<brief_summary>The objectives of this study are as follows: In patients with primary Type II Achalasia, following a single 5-mg dose of IW-1701, - To assess the safety and tolerability - To determine the effects on measures of esophageal function by high-resolution impedance manometry (HRIM) - To determine the pharmacokinetic (PK) parameters, Cmax, Tmax, and AUClast</brief_summary>
	<brief_title>Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type II Achalasia</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Achalasia</mesh_term>
	<criteria>Patient is a male or female between 18 and 65 years old at the Screening Visit. Patient has a diagnosis of primary Type II achalasia. Patient has no contraindications to the performance of the baseline and postdose HRIM procedures per Investigator discretion. Patient has had any prior esophageal, periesophageal, or gastric surgery, prior pneumatic dilation, or prior esophageal injection of botulinum toxin or sclerosing agent. (Patients with prior bougie dilation â‰¤ 2 cm will be allowed) Patients with malignant or premalignant esophageal lesions. Patient has taken any drug that can affect GI motility in the 72 hours before Checkin through Discharge from the clinic. Other exclusion criteria specified in the protocol.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>